JEITO CAPITAL SAS
JEITO CAPITAL SAS is a Series C+ and clinical-stage fund in the US and Europe writing up to $175M checks into biopharma, biotechnology, drug-discovery, life-sciences, medical-innovation, oncology, autoimmune-and-inflammatory-diseases, ophthalmology, cardiology, obesity, reproductive-medicine-and-womens-health, neuromuscular, neurodegenerative and cardio-metabolic-diseases.
- Stages
- Series C+, clinical-stage
- Sectors
- biopharma, biotechnology, drug-discovery, life-sciences, medical-innovation, oncology, autoimmune-and-inflammatory-diseases, ophthalmology, cardiology, obesity, reproductive-medicine-and-womens-health, neuromuscular, neurodegenerative, cardio-metabolic-diseases
- Check size
- up to $175M
- Invests in
- US-wide, Europe
- Round role
- Leads rounds
Thesis
Jeito Capital SAS is an independent European biopharma investment firm founded in 2018, headquartered in Paris, France. With €1.6 billion in AUM as of April 2026, built from Jeito I ($630M) and Jeito II (€1B+/$1.2B), the firm focuses on financing and accelerating medical innovation through a patient-benefit-driven approach. They primarily target high-potential, clinical-stage biopharmaceutical companies developing breakthrough therapies for severe diseases with high unmet medical needs. Their therapeutic areas of interest are broad, including oncology, autoimmune and inflammatory diseases, ophthalmology, cardiology, obesity, reproductive medicine and women's health, neuromuscular, neurodegenerative, and cardio-metabolic diseases. Jeito Capital's geographic scope is primarily Europe, with a presence in the United States. They often lead investments and provide follow-on capital, with a typical check size of up to €150 million ($175 million) per company, aiming to back 15-20 clinical-stage biopharma companies with their latest fund. The firm boasts a multidisciplinary team of over 30 healthcare professionals with extensive experience across the drug development value chain.
Common questions
Does JEITO CAPITAL SAS invest at the Series C+ stage?
Yes. JEITO CAPITAL SAS lists Series C+ and clinical-stage among the stages it invests in.
What check size does JEITO CAPITAL SAS write?
JEITO CAPITAL SAS writes up to $175M checks.
Where does JEITO CAPITAL SAS invest?
JEITO CAPITAL SAS invests in the US and Europe.